ESMO 2020: Nivolumab plus Cabozantinib Outperforms Sunitinib in Advanced Renal Cell Carcinoma
Study authors suggest the combination be considered a first-line option
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.